on Theranexus (EPA:ALTHX)
Allinvest Securities Backs THX Pharma with Optimistic Buy Recommendation
On June 16, 2026, Allinvest Securities initiated coverage of THX Pharma, a leading biopharmaceutical entity in rare neurological diseases. The research report titled "THX Pharma: Transformed profile, reconfigured risk/reward" recommends buying THX Pharma stock, setting a target price of €10.4. This signals a potential 226% increase from its closing price of €3.205 on June 15, 2026.
The recommendation acknowledges THX Pharma's recent shifts, transitioning from a broad neurology biotech to a focused rare-disease platform, underlined by strategic partnerships with Exeltis and Biocodex. These alliances have enhanced THX Pharma's financial and industrial credibility.
This development marks THX Pharma's reinforced commitment to transparency and visibility in the stock market, with coverage now by both Portzamparc and Allinvest Securities.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Theranexus news